Several possible studies
Story checked
Five-treatment radiation provides excellent long-term prostate cancer control (opens in a new tab)
news-medical.net · 2026-09-28
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Five-treatment radiation provides excellent long-term prostate cancer control
news-medical.net · 2026-09-28
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedFive-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.View evidenceHide evidence
As statedexcellent long-term cancer control; fewer urinary and sexual side effects
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedAfter a median follow-up of eight years, 91% of patients treated with SBRT remained free from biochemical or clinical failure, compared with 84% treated with surgery; the difference was not statistically significant.View evidenceHide evidence
As stated91% vs 84% failure-free at eight years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedPACE-A is presented as the first phase 3 randomized trial to directly compare SBRT with prostatectomy for localized prostate cancer, enrolling 123 patients at eight centers in the United Kingdom between 2012 and 2022, mostly with low/intermediate-risk disease.View evidenceHide evidence
As stated123 patients; eight centers; 2012-2022
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedThe trial found 13 failures in total, including five in the SBRT group and eight in the surgery group; five-year freedom from failure was 94% with SBRT and 95% with prostatectomy, and the trial was not designed to establish noninferiority for cancer control.View evidenceHide evidence
As stated13 failures; 94% vs 95% at five years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedAt five years, 8% of patients treated with SBRT reported using at least one urinary pad, compared with 48% of those treated with surgery, and moderate or substantial bowel problems were uncommon in both groups.View evidenceHide evidence
As stated8% vs 48% urinary pad use at five years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedAt five years, median erectile-function scores on a 25-point scale were 19 after SBRT and 5 after prostatectomy, with patient-reported sexual-function scores remaining significantly better after SBRT.View evidenceHide evidence
As stated19 vs 5 on a 25-point erectile-function scale
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe findings apply primarily to patients with favorable intermediate-risk prostate cancer, and patients with higher-risk disease may require a different approach.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
Impact of 18F-DCFPyL-PSMA PET/CT on Radiotherapy Planning and Treatment Intensification in Occult Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Cancers · 2026 · PubMed
Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure
Frontiers in Oncology · 2016 · Crossref
Recurrent Pubic Osteomyelitis and Urosymphyseal Fistula in a Prostate Cancer Survivor: A Multidisciplinary Management Challenge.
Journal of Community Hospital Internal Medicine Perspectives · 2026 · PubMed
280 oral Post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3N0 prostate cancer (PC)(EORTC 22911)
Radiotherapy and Oncology · 2004 · Crossref
Long-term control after stereotactic body radiotherapy for perineal recurrence of prostate cancer after radical prostatectomy and radiotherapy: A case report and review of the literature.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique · 2026 · PubMed, Crossref
And 10 more candidates considered.